These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37063883)

  • 21. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
    Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
    Front Immunol; 2017; 8():1367. PubMed ID: 29104575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy.
    Minegishi Y; Haga Y; Ueda K
    Cancer Sci; 2024 Apr; 115(4):1048-1059. PubMed ID: 38382459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation.
    Goncalves G; Mullan KA; Duscharla D; Ayala R; Croft NP; Faridi P; Purcell AW
    Front Immunol; 2021; 12():645770. PubMed ID: 33968037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery.
    Zhang B; Bassani-Sternberg M
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.
    Caron E; Kowalewski DJ; Chiek Koh C; Sturm T; Schuster H; Aebersold R
    Mol Cell Proteomics; 2015 Dec; 14(12):3105-17. PubMed ID: 26628741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.
    Chong C; Marino F; Pak H; Racle J; Daniel RT; Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
    Mol Cell Proteomics; 2018 Mar; 17(3):533-548. PubMed ID: 29242379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
    Marino F; Semilietof A; Michaux J; Pak HS; Coukos G; Müller M; Bassani-Sternberg M
    Front Immunol; 2020; 11():1981. PubMed ID: 32983136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IMBAS-MS Discovers Organ-Specific HLA Peptide Patterns in Plasma.
    Wahle M; Thielert M; Zwiebel M; Skowronek P; Zeng WF; Mann M
    Mol Cell Proteomics; 2024 Jan; 23(1):100689. PubMed ID: 38043703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.
    Wang M; Tang ST; Stryhn A; Justesen S; Larsen MV; Dziegiel MH; Lewinsohn DM; Buus S; Lund O; Claesson MH
    Immunology; 2011 Apr; 132(4):482-91. PubMed ID: 21294723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
    Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
    Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
    Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
    Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.
    Sonpavde G; Wang M; Peterson LE; Wang HY; Joe T; Mims MP; Kadmon D; Ittmann MM; Wheeler TM; Gee AP; Wang RF; Hayes TG
    Invest New Drugs; 2014 Apr; 32(2):235-242. PubMed ID: 23609828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mass spectrometry and peptide-based vaccine development.
    Ovsyannikova IG; Johnson KL; Bergen HR; Poland GA
    Clin Pharmacol Ther; 2007 Dec; 82(6):644-52. PubMed ID: 17971823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide Modification Diminishes HLA Class II-restricted CD4
    Doonan BP; Amria S; Bethard JR; Banik NL; Hathaway-Schrader JD; Haque A
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.
    Yaciuk JC; Skaley M; Bardet W; Schafer F; Mojsilovic D; Cate S; Stewart CJ; McMurtrey C; Jackson KW; Buchli R; Olvera A; Cedeño S; Plana M; Mothe B; Brander C; West JT; Hildebrand WH
    J Virol; 2014 Nov; 88(22):12992-3004. PubMed ID: 25165114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis.
    Sirois I; Isabelle M; Duquette JD; Saab F; Caron E
    J Vis Exp; 2021 Oct; (176):. PubMed ID: 34723952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry.
    Phulphagar KM; Ctortecka C; Jacome ASV; Klaeger S; Verzani EK; Hernandez GM; Udeshi ND; Clauser KR; Abelin JG; Carr SA
    Mol Cell Proteomics; 2023 Jun; 22(6):100563. PubMed ID: 37142057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COSMIC-based mutation database enhances identification efficiency of HLA-I immunopeptidome.
    Wang F; Zhang Z; Mao M; Yang Y; Xu P; Lu S
    J Transl Med; 2024 Feb; 22(1):144. PubMed ID: 38336780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.